Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro

International Journal of Cancer

Volumn 100, Issue 2, 2002, Pages 238-243

  Raitanen, Misa ^a,b   Rantanen, Virpi ^b,c   Kulmala, Jarmo ^a   Helenius, Hans ^b   Grénman, Reidar ^a,b   Grénman, Seija ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c TURKU CITY HOSPITAL   (Finland)

Author keywords

Cisplatin; Clonogenic assay; Paclitaxel; Squamous cell carcinoma; Supra additive effect; Vulvar carcinoma

Indexed keywords

CISPLATIN; PACLITAXEL;

AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CHEMOSENSITIVITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; VULVA CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; PACLITAXEL; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; VULVAR NEOPLASMS;

EID: 0037054945     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10472     Document Type: Article

References (50)

1. Carcinoma of the vulva
2. Radiation response of vulvar squamous cell carcinoma (UM-SCV-1A,UM-SCV-1B, UM-SCV-2 and A-431) cells in vitro
3. The use of concomitant chemotherapy and radiotherapy prior to surgery in advanced stage carcinoma of the vulva
4. Concurrent radiation and chemotherapy in vulvar carcinoma
5. Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva
6. Concurrent radiation therapy and chemotherapy in the treatment of primary squamous cell carcinoma of the vulva
7. Preliminary results of chemoradiation as a primary treatment for vulvar carcinoma
8. Phase II trials of cisplatin and piperazinedione in advanced or recurrent squamous cell carcinoma of the vulva: A Gynecologic Oncology Group study
9. Cisplatin (P), bleomycin (B), and methotrexate (M) preoperative chemotherapy in locally advanced vulvar carcinoma
10. Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer
11. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer
12. Multimodality therapy of patients with locally advanced squamous cell carcinoma of the head and neck: Preliminary results of two pilot trials using paclitaxel and cisplatin
13. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix - A phase II study
14. The Gynecologic Oncology Group experience in ovarian cancer
15. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A gynecologic oncology group study
16. In vitro chemosensitivity of four new carcinoma of the cervix cell lines: Relationship to radiosensitivity
17. Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck
18. In vitro antiproliferative activity of docetaxel (Taxotere®), paclitaxel (Taxol®) and cisplatin against human tumour and normal bone marrow cells
19. In vitro concurrent paclitaxel and radiation of four vulvar squamous cell carcinoma cell lines
20. Vulvar squamous cell carcinoma cell lines are sensitive to paclitaxel in vitro
21. Paclitaxel combined with fractionated radiation in vitro; a study with vulvar squamous cell carcinoma cell lines
22. Taxol stabilizes microtubules in mouse fibroblast cells
23. Quantitative estimation of cisplatin-induced DNA interstrand crosslinks and their repair on mammalian cells
24. Sequences of taxol and cisplatin: A phase I and pharmacologic study
25. Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines
26. Phenotypic characterization, karyotype analysis and in vitro tamoxifen sensitivity of new ER-negative vulvar carcinoma cell lines, UM.SCV-1A and UM-SCV-1B
27. Consistent chromosome abnormalities in squamous cell carcinoma of the vulva
28. Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution
29. Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines
30. Effects of paclitaxel with or without cremophor EL on cellular clonogenic survival and apoptosis
31. Fundamental studies with cisplatin
32. Taxol: A novel investigational antimicrotubule agent
33. Endometrial cancer cell lines are sensitive to paclitaxel
34. Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96-well plate clonogenic assay
35. Pharmacokinetics and protein-binding of cis-chlorodiamineplatinum(II) administrated as a one hour or as a twenty-four hour infusion
36. Sequence-dependent cytotoxicity between cisplatin and the antimicrotubule agents taxol and vincristine
37. Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells
38. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine
39. Evaluation of paclitaxel (Taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay
40. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro
41. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells
42. In vitro cytotoxicity in ovarian cancer of low-dose continuous exposure to microtubule inhibitors (paclitaxel/taxotere) combined with cisplatin
43. Schedule-dependent synergism of Taxol or Taxotere with edatrexate against breast cancer cells in vitro
44. Apparent in vitro antagonism between cisplatin and taxol
45. Chromosomal aberrations identified in culture of squamous cell carcinomas are confirmed by fluorescence in situ hybridization
46. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer
47. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1000 patients registered to National Cancer Institute treatment referral center 9103
48. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
49. Comparative in vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines
50. Platinum-Taxol non-cross resistance in epithelial ovarian cancer